Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) announced inducement stock option awards under its 2025 Inducement Plan on October 15, 2025.

The Compensation Committee granted options to purchase an aggregate of 1,093,300 shares to 65 employees. Options carry an exercise price of $1.49, equal to the closing price on October 7, 2025, have a 10-year term, and vest over four years (25% at one year, then 36 equal monthly installments), subject to continued service. Grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4).

LONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 1,093,300 shares of its common stock to 65 employees pursuant to the Company’s 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.49 per share, which is equal to the closing price of Autolus’ common stock on October 7, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter, subject to the employee's continued service with Autolus through the applicable vesting dates.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:  

Amanda Cray 
Executive Director, Investor Relations & External Communications
+1 617-967-0207 
a.cray@autolus.com 

FAQ

How many stock options did Autolus (AUTL) grant on October 15, 2025?

Autolus granted options to purchase an aggregate of 1,093,300 shares on October 15, 2025.

Who received the Autolus (AUTL) inducement option awards and how many recipients were there?

The awards were granted to 65 employees as inducements to become employees of Autolus.

What is the exercise price and effective pricing date for Autolus (AUTL) options granted in October 2025?

The exercise price is $1.49 per share, equal to Autolus’ closing price on October 7, 2025.

What are the term and vesting schedule for the Autolus (AUTL) October 2025 option grants?

Each option has a 10-year term and vests over 4 years: 25% at one year, then monthly vesting over the remaining 36 months.

Why were Autolus (AUTL) stock options issued under the 2025 Inducement Plan?

The options were granted as inducement awards to employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Do Autolus (AUTL) option awards require continued employment to vest?

Yes, vesting is subject to the employee's continued service through the applicable vesting dates.